Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-365]

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013

AGENCY:

Drug Enforcement Administration (DEA), Department of Justice.

ACTION:

Notice with request for comments.

SUMMARY:

This notice proposes to adjust the 2013 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act (CSA) and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, as well as to establish the 2013 aggregate production quotas for three recently temporarily scheduled substances.

DATES:

Electronic comments must be submitted and written comments must be postmarked on or before July 22, 2013. The electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period.

ADDRESSES:

To ensure proper handling of comments, please reference “Docket No. DEA-365” on all electronic and written correspondence. DEA encourages all comments be submitted electronically through

http://www.regulations.gov

using the electronic comment form provided on that site. An electronic copy of this document is also available at

http://www.regulations.gov

for easy reference. Paper comments that duplicate the electronic submission are not necessary and are strongly discouraged as all comments submitted to

www.regulations.gov

will be posted for public review and are part of the official docket record. Should you, however, wish to submit written comments via regular or express mail, they should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152.

FOR FURTHER INFORMATION CONTACT:

John W. Partridge, Executive Assistant, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152; Telephone: (202) 307-7165.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

All comments received are considered part of the public record and made available for public inspection online at

http://www.regulations.gov

and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “PERSONAL IDENTIFYING INFORMATION” in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase “CONFIDENTIAL BUSINESS INFORMATION” in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted online or made available in the public docket.

Personal identifying information and confidential business information identified and located as set forth above will be redacted, and the comment, in redacted form, will be posted online and placed in the DEA's public docket file. Please note that the Freedom of Information Act applies to all comments received. If you wish to inspect the agency's public docket file in person by appointment, please see the

For Further Information Contact

paragraph.

Background

Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA through 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. DEA published the 2013 established aggregate production quotas for controlled substances in schedules I and II and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the

Federal Register

(77 FR 59980) on October 1, 2012. That notice stipulated that, as provided for in 21 CFR 1303.13 and 21 CFR 1315.13, all aggregate production quotas and assessments of annual need are subject to adjustment.

Analysis for Proposed Aggregate Production Quotas for Temporarily Scheduled Substances

On May 16, 2013, the Deputy Administrator issued a final order to temporarily schedule three synthetic cannabinoids in schedule I of the CSA: (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

(UR-144); [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11); and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48). See 78 FR 28735. DEA has received applications for registration and quota for these temporarily scheduled substances. In examining the information provided by the applicants, along with other information, DEA finds that there is a current need for these substances. Aggregate production quotas represent those quantities of schedule I and II controlled substances to be manufactured in the United States in 2013 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. As such, pursuant to 21 U.S.C. 826(a), the Deputy Administrator must determine the total quantity and establish production quotas for each of the three temporarily scheduled substances.

In making this determination, the Deputy Administrator has taken into account the criteria that DEA is required to consider in accordance with 21 U.S.C. 826(a) and 21 CFR 1303.11. DEA proposes the aggregate production quotas for these three temporarily scheduled substances by considering: (1) Total estimated net disposal of each substance by all manufacturers; (2) estimated trends in the national rate of net disposal; (3) total estimated inventories of the basic class and of all substances manufactured from the class; (4) projected demand for each class as indicated by procurement quotas requested pursuant to 21 CFR 1303.12; and (5) other factors affecting medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Deputy Administrator finds relevant. These quotas do not include imports of controlled substances for use in industrial processes.

Analysis for Proposed Revised 2013 Aggregate Production Quotas and Assessment of Annual Needs

DEA proposes to adjust the established 2013 aggregate production quotas for some schedule I and II controlled substances to be manufactured in the United States in 2013 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes. DEA is not proposing to adjust the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine at this time.

In proposing the adjustment, DEA has taken into account the criteria that DEA is required to consider in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. DEA determines whether to propose an adjustment of the aggregate production quotas for basic classes of schedule I and II controlled substances and ephedrine, pseudoephedrine, and phenylpropanolamine by considering: (1) Changes in demand for the basic class, changes in the national rate of net disposal for the class, and changes in the rate of net disposal by the registrants holding individual manufacturing quotas for the class; (2) whether any increased demand or changes in the national or individual rates of net disposal are temporary, short term, or long term; (3) whether any increased demand can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand will result in excessive inventory accumulation by all persons registered to handle the class; and (5) other factors affecting the medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Deputy Administrator finds relevant.

DEA also considered updated information obtained from 2012 year-end inventories, 2012 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information made available to DEA after the initial aggregate production quotas and assessment of annual needs had been established. Other factors DEA considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of both bulk and finished dosage form manufacturers, and other pertinent information. In determining the proposed revised 2013 assessment of annual needs, DEA used the calculation methodology previously described in the 2010 and 2011 assessment of annual needs (74 FR 60294 and 75 FR 79407, respectively).

As described in the previously published notice establishing the 2013 aggregate production quotas and assessment of annual needs, DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, DEA has included in all proposed revised schedule II aggregate production quotas, and certain schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The resulting revised established aggregate production quota will reflect these included amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by DEA. DEA does not anticipate utilizing the reserve in the absence of these circumstances.

The Deputy Administrator, therefore, proposes that the year 2013 aggregate production quotas for the three temporarily scheduled substances be established, and to adjust the 2013 aggregate production quotas for some schedule I and II controlled substances and ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class

Previously

established 2013 quotas

Proposed or proposed

adjusted

2013 quotas

Temporarily Scheduled Substances

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)

N/A

15 g.

[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11)

N/A

15 g.

N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48)

N/A

15 g.

Schedule I

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)

45 g

No change.

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)

45 g

No change.

1-[1-(2-Thienyl)cyclohexyl]piperidine

5 g

No change.

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)

45 g

No change.

1-Butyl-3-(1-naphthoyl)indole (JWH-073)

45 g

No change.

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)

45 g

No change.

1-Hexyl-3-(1-naphthoyl)indole (JWH-019)

45 g

No change.

1-Methyl-4-phenyl-4-propionoxypiperidine

2 g

No change.

1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)

45 g

No change.

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)

45 g

No change.

1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)

45 g

No change.

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)

45 g

No change.

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)

45 g

No change.

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4)

45 g

No change.

1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)

45 g

No change.

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)

15 g

No change.

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)

15 g

No change.

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)

15 g

No change.

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)

15 g

No change.

2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)

15 g

No change.

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)

15 g

No change.

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)

15 g

No change.

2,5-Dimethoxy-4-ethylamphetamine (DOET)

12 g

No change.

2,5-Dimethoxy-4-n-propylthiophenethylamine

12 g

No change.

2,5-Dimethoxyamphetamine

12 g

No change.

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)

15 g

No change.

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)

15 g

No change.

3,4,5-Trimethoxyamphetamine

12 g

No change.

3,4-Methylenedioxyamphetamine (MDA)

30 g

No change.

3,4-Methylenedioxymethamphetamine (MDMA)

35 g

50 g.

3,4-Methylenedioxy-N-ethylamphetamine (MDEA)

24 g

No change.

3,4-Methylenedioxy-N-methylcathinone (methylone)

35 g

No change.

3,4-Methylenedioxypyrovalerone (MDPV)

25 g

No change.

3-Methylfentanyl

2 g

No change.

3-Methylthiofentanyl

2 g

No change.

4-Bromo-2,5-dimethoxyamphetamine (DOB)

12 g

No change.

4-Bromo-2,5-dimethoxyphenethylamine (2-CB)

12 g

No change.

4-Methoxyamphetamine

88 g

No change.

4-Methyl-2,5-dimethoxyamphetamine (DOM)

12 g

25 g.

4-Methylaminorex

12 g

No change.

4-Methyl-N-methylcathinone (mephedrone)

25 g

No change.

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol

68 g

No change.

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47, 497 C8-homolog)

53 g

No change.

5-Methoxy-3,4-methylenedioxyamphetamine

12 g

No change.

5-Methoxy-N,N-diisopropyltryptamine

12 g

No change.

5-Methoxy-N,N-dimethyltryptamine

10 g

No change.

Acetyl-alpha-methylfentanyl

2 g

No change.

Acetyldihydrocodeine

2 g

No change.

Acetylmethadol

2 g

No change.

Allylprodine

2 g

No change.

Alphacetylmethadol

2 g

No change.

Alpha-ethyltryptamine

12 g

No change.

Alphameprodine

2 g

No change.

Alphamethadol

2 g

No change.

Alpha-methylfentanyl

2 g

No change.

Alpha-methylthiofentanyl

2 g

No change.

Alpha-methyltryptamine (AMT)

12 g

No change.

Aminorex

12 g

No change.

Benzylmorphine

2 g

No change.

Betacetylmethadol

2 g

No change.

Beta-hydroxy-3-methylfentanyl

2 g

No change.

Beta-hydroxyfentanyl

2 g

No change.

Betameprodine

2 g

No change.

Betamethadol

2 g

No change.

Betaprodine

2 g

No change.

Bufotenine

3 g

No change.

Cathinone

12 g

No change.

Codeine-N-oxide

602 g

No change.

Desomorphine

5 g

No change.

Diethyltryptamine

12 g

No change.

Difenoxin

50 g

No change.

Dihydromorphine

3,300,000 g

No change.

Dimethyltryptamine

18 g

No change.

Gamma-hydroxybutyric acid

46,250,000 g

No change.

Heroin

25 g

No change.

Hydromorphinol

54 g

No change.

Hydroxypethidine

2 g

No change.

Ibogaine

5 g

No change.

Lysergic acid diethylamide (LSD)

30 g

No change.

Marihuana

21,000 g

No change.

Mescaline

13 g

No change.

Methaqualone

10 g

No change.

Methcathinone

14 g

No change.

Methyldihydromorphine

2 g

No change.

Morphine-N-oxide

655 g

No change.

N,N-Dimethylamphetamine

12 g

No change.

N-Benzylpiperazine

15 g

No change.

N-Ethylamphetamine

12 g

No change.

N-Hydroxy-3,4-methylenedioxyamphetamine

12 g

No change.

Noracymethadol

2 g

No change.

Norlevorphanol

52 g

No change.

Normethadone

2 g

No change.

Normorphine

18 g

No change.

Para-fluorofentanyl

2 g

No change.

Phenomorphan

2 g

No change.

Pholcodine

2 g

No change.

Properidine

2 g

No change.

Psilocybin

2 g

10 g.

Psilocyn

4 g

No change.

Tetrahydrocannabinols

491,000 g

No change.

Thiofentanyl

2 g

No change.

Tilidine

10 g

No change.

Trimeperidine

2 g

No change.

Schedule II

1-Phenylcyclohexylamine

3 g

No change.

1-Piperdinocyclohexanecarbonitrile

21 g

No change.

4-Anilino-N-phenethyl-4-piperidine (ANPP)

2,250,000 g

No change.

Alfentanil

38,250 g

No change.

Alphaprodine

3 g

No change.

Amobarbital

9 g

No change.

Amphetamine (for conversion)

22,875,000 g

No change.

Amphetamine (for sale)

42,625,000 g

47,186,000 g.

Carfentanil

6 g

No change.

Cocaine

240,000 g

No change.

Codeine (for conversion)

81,250,000 g

No change.

Codeine (for sale)

49,506,250 g

No change.

Dextropropoxyphene

19 g

No change.

Dihydrocodeine

250,000 g

No change.

Diphenoxylate

750,000 g

No change.

Ecgonine

127,500 g

144,000 g.

Ethylmorphine

3 g

No change.

Fentanyl

2,108,750 g

No change.

Glutethimide

3 g

No change.

Hydrocodone (for sale)

99,625,000 g

No change.

Hydromorphone

5,968,750 g

No change.

Isomethadone

5 g

No change.

Levo-alphacetylmethadol (LAAM)

4 g

No change.

Levomethorphan

6 g

No change.

Levorphanol

4,500 g

No change.

Lisdexamfetamine

21,000,000 g

No change.

Meperidine

6,875,000 g

No change.

Meperidine Intermediate—A

6 g

No change.

Meperidine Intermediate—B

11 g

No change.

Meperidine Intermediate—C

6 g

No change.

Metazocine

6 g

No change.

Methadone (for sale)

25,000,000 g

33,125,000 g.

Methadone Intermediate

32,500,000 g

40,500,000 g.

Methamphetamine

3,912,500 g

No change.

[987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,863,750 grams for methamphetamine mostly for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)]

Methylphenidate

80,750,000 g

96,750,000 g.

Morphine (for conversion)

103,750,000 g

91,250,000 g.

Morphine (for sale)

60,250,000 g

No change.

Nabilone

25,628 g

No change.

Noroxymorphone (for conversion)

9,000,000 g

No change.

Noroxymorphone (for sale)

508,750 g

1,262,500 g.

Opium (powder)

91,250 g

No change.

Opium (tincture)

1,287,500 g

No change.

Oripavine

22,750,000 g

No change.

Oxycodone (for conversion)

10,250,000 g

No change.

Oxycodone (for sale)

131,500,000 g

153,750,000 g.

Oxymorphone (for conversion)

18,375,000 g

No change.

Oxymorphone (for sale)

6,875,000 g

No change.

Pentobarbital

42,500,000 g

No change.

Phenazocine

6 g

No change.

Phencyclidine

30 g

No change.

Phenmetrazine

3 g

No change.

Phenylacetone

20,000,000 g

29,628,750 g.

Racemethorphan

3 g

No change.

Remifentanil

3,750 g

No change.

Secobarbital

215,003 g

No change.

Sufentanil

6,255 g

No change.

Tapentadol

13,750,000 g

No change.

Thebaine

145,000,000 g

No change.

List I Chemicals

Ephedrine (for conversion)

15,100,000 g

No change.

Ephedrine (for sale)

3,500,000 g

No change.

Phenylpropanolamine (for conversion)

25,700,000 g

No change.

Phenylpropanolamine (for sale)

6,100,000 g

No change.

Pseudoephedrine (for sale)

225,000,000 g

No change.

The Deputy Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Deputy Administrator may adjust the 2013 aggregate production quotas and assessment of annual needs as needed.

Comments

Pursuant to 21 CFR 1303.11 and 21 CFR 1315.11, any interested person may submit written comments on or objections to these proposed determinations. Based on comments received in response to this Notice, the Deputy Administrator may hold a public hearing on one or more issues raised. In the event the Deputy Administrator decides in his sole discretion to hold such a hearing, the Deputy Administrator will publish a notice of any such hearing in the

Federal Register

. After consideration of any comments and after a hearing, if one is held, the Deputy Administrator will publish in the

Federal Register

a Final Order establishing any adjustment of 2013 aggregate production quota for each basic class of controlled substance and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

Dated: June 14, 2013.

Thomas M. Harrigan,

Deputy Administrator.

[FR Doc. 2013-14723 Filed 6-19-13; 8:45 am]

BILLING CODE 4410-09-P